Diagnostic and prognostic significance of myositis-specific autoantibodies in idiopathic inflammatory myopathies

Read full text Summarise with VIRAT
Authors: Ji-Yon Kim, Hsueh‐Wen Hsueh, Eun-Jae Lee, Hyunjin Kim, Young‐Min Lim
Cited by: 0
References: 95

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Idiopathic inflammatory myopathies (IIMs) are heterogeneous immune-mediated muscle disorders with variable extramuscular manifestations and outcomes. Myositis-specific auto-antibodies (MSAs) have transformed the IIM field by enabling a serology-informed taxonomy based on distinct clinical phenotypes, prognostic trajectories, and therapeutic responses. Anti-Jo-1 and other antisynthetase antibodies characterize interstitial lung disease (ILD)-prone forms of disease; anti-MDA5 identifies patients at risk of rapidly progressive ILD and early mortality; anti-TIF1-γ and anti-NXP2 are indicative of cancer-associated myositis; anti-SRP and anti-HMGCR delineate necrotizing myopathies; and anti-cN1A supports the diagnosis of inclusion-body myositis. Beyond diagnosis, MSA profiles provide prognostic information, including about survival, relapse risk, and organ-specific complications, and they are increasingly being used to guide treatment decisions and predict biologic responsiveness. This review summarizes the diagnostic, prognostic, and therapeutic implications of MSAs across the IIM spectrum and highlight their growing importance in clinical practice for risk stratification and patient management.

Fields of Study & Subjects

Inflammatory Myopathies and Dermatomyositis Myasthenia Gravis and Thymoma Viral Infections and Immunology Research

Publication details

Journal / source
Annals of Clinical Neurophysiology
Volume
28
Issue
1
Pages
33–49
Publication date
27 March 2026
Language
EN